KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Shares Outstanding (Diluted Average) (2016 - 2025)

Travere Therapeutics' Shares Outstanding (Diluted Average) history spans 13 years, with the latest figure at $89.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 13.09% year-over-year to $89.2 million; the TTM value through Dec 2025 reached $89.2 million, up 13.09%, while the annual FY2025 figure was $89.2 million, 13.09% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $89.2 million in Q4 2025 per TVTX's latest filing, down from $102.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $102.6 million in Q3 2025 to a low of $56.3 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $73.0 million, with a median of $73.2 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): surged 35.31% in 2021, then increased 1.53% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $59.8 million in 2021, then grew by 6.56% to $63.8 million in 2022, then rose by 16.48% to $74.3 million in 2023, then rose by 6.22% to $78.9 million in 2024, then grew by 13.09% to $89.2 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Shares Outstanding (Diluted Average) are $89.2 million (Q4 2025), $102.6 million (Q3 2025), and $88.7 million (Q2 2025).